基于小组的干预减少慢性疼痛阿片类药物使用:一项随机临床试验
这项多中心随机临床试验在英格兰191个初级保健中心纳入608名服用强阿片类药物治疗慢性非恶性疼痛的成人,1:1随机分为常规护理组或3天小组课程加12个月一对一支持组。主要终点之一PROMIS-PI-SF-8a评分在12个月时两组间无统计学显著差异(组间均数差-0.52,95%CI -1.94至0.89;P=0.15)。阿片类药物停用率干预组29%(65/225) vs 常规护理组7%(15/208),OR 5.55(95%CI 2.80至10.99),绝对差21.7%(95%CI 14.8%至28.6%),P<0.001。严重不良事件干预组8%(25/305) vs 常规护理组5%(16/303),最常见为胃肠道和运动/肌肉骨骼事件。结论认为该干预显著减少患者报告的阿片类药物使用,但对感知的疼痛干扰无影响。
要点
- 在608名慢性非恶性疼痛成人中,12个月时干预组阿片停药率29%(65/225) vs 常规护理组7%(15/208),OR 5.55(95%CI 2.80-10.99),P<0.001。
- PROMIS-PI-SF-8a评分12个月时干预组下降4.1、常规护理组下降3.17,组间均数差-0.52(95%CI -1.94至0.89),P=0.15,未达统计学显著。
- 严重不良事件干预组8%(25/305) vs 常规护理组5%(16/303),最常见为胃肠道(2% vs 0%)和运动/肌肉骨骼(2% vs 1%)。
- 干预组4人(1%)因可能或 probable 阿片戒断症状(气短、潮热、发热和疼痛、小肠出血、过量自杀未遂)接受额外医疗照护。
适用人群与场景
- 服用强阿片类药物(丁丙诺啡、地匹哌酮、吗啡、二醋吗啡、芬太尼、氢吗啡酮、美沙酮、羟考酮、阿片全碱、喷他佐辛、哌替啶、他喷他多和曲马多)治疗慢性非恶性疼痛的成人。
- 研究在英格兰191个初级保健中心进行,纳入608名成人,平均年龄61岁,女性362名(60%),每日吗啡等效剂量中位数46 mg(IQR 25至79)。
处置流程与药物剂量
- 干预组接受3天小组课程,强调技能学习和教育,并补充由护士和非专业人员提供的一对一支持,持续12个月。
- 常规护理组接受常规护理。
红旗征与不能漏的情况
- 干预组4人(1%)因可能或 probable 阿片戒断症状(气短、潮热、发热和疼痛、小肠出血、过量自杀未遂)接受额外医疗照护。
研究设计与关键结果
- 多中心随机临床试验,纳入608名成人,1:1随机分为常规护理组或3天小组课程加12个月一对一支持组;440人(72%)完成12个月随访。
- 主要终点PROMIS-PI-SF-8a评分12个月时干预组下降4.1、常规护理组下降3.17,组间均数差-0.52(95%CI -1.94至0.89),P=0.15。
- 12个月时阿片停药干预组65/225(29%) vs 常规护理组15/208(7%),OR 5.55(95%CI 2.80至10.99),绝对差21.7%(95%CI 14.8%至28.6%),P<0.001。
- 严重不良事件干预组8%(25/305) vs 常规护理组5%(16/303);最常见为胃肠道(干预组2% vs 常规护理组0%)和运动/肌肉骨骼(干预组2% vs 常规护理组1%)。
证据类型、等级与局限
- 研究类型:多中心随机临床试验。
- 试验注册:ISRCTN49470934。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在慢性非恶性疼痛患者中,与常规护理相比,包含小组和个体支持及技能学习的小组教育干预显著减少患者报告的阿片类药物使用,但对感知的疼痛干扰无影响。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Opioid use for chronic nonmalignant pain can be harmful.
OBJECTIVE: To test whether a multicomponent, group-based, self-management intervention reduced opioid use and improved pain-related disability compared with usual care.
DESIGN, SETTING, AND PARTICIPANTS: Multicentered, randomized clinical trial of 608 adults taking strong opioids (buprenorphine, dipipanone, morphine, diamorphine, fentanyl, hydromorphone, methadone, oxycodone, papaveretum, pentazocine, pethidine, tapentadol, and tramadol) to treat chronic nonmalignant pain. The study was conducted in 191 primary care centers in England between May 17, 2017, and January 30, 2019. Final follow-up occurred March 18, 2020.
INTERVENTION: Participants were randomized 1:1 to either usual care or 3-day-long group sessions that emphasized skill-based learning and education, supplemented by 1-on-1 support delivered by a nurse and lay person for 12 months.
MAIN OUTCOMES AND MEASURES: The 2 primary outcomes were Patient-Reported Outcomes Measurement Information System Pain Interference Short Form 8a (PROMIS-PI-SF-8a) score (T-score range, 40.7-77; 77 indicates worst pain interference; minimal clinically important difference, 3.5) and the proportion of participants who discontinued opioids at 12 months, measured by self-report.
RESULTS: Of 608 participants randomized (mean age, 61 years; 362 female [60%]; median daily morphine equivalent dose, 46 mg [IQR, 25 to 79]), 440 (72%) completed 12-month follow-up. There was no statistically significant difference in PROMIS-PI-SF-8a scores between the 2 groups at 12-month follow-up (-4.1 in the intervention and -3.17 in the usual care groups; between-group difference: mean difference, -0.52 [95% CI, -1.94 to 0.89]; P = .15). At 12 months, opioid discontinuation occurred in 65 of 225 participants (29%) in the intervention group and 15 of 208 participants (7%) in the usual care group (odds ratio, 5.55 [95% CI, 2.80 to 10.99]; absolute difference, 21.7% [95% CI, 14.8% to 28.6%]; P < .001). Serious adverse events occurred in 8% (25/305) of the participants in the intervention group and 5% (16/303) of the participants in the usual care group. The most common serious adverse events were gastrointestinal (2% in the intervention group and 0% in the usual care group) and locomotor/musculoskeletal (2% in the intervention group and 1% in the usual care group). Four people (1%) in the intervention group received additional medical care for possible or probable symptoms of opioid withdrawal (shortness of breath, hot flushes, fever and pain, small intestinal bleed, and an overdose suicide attempt).
CONCLUSIONS AND RELEVANCE: In people with chronic pain due to nonmalignant causes, compared with usual care, a group-based educational intervention that included group and individual support and skill-based learning significantly reduced patient-reported use of opioids, but had no effect on perceived pain interference with daily life activities.
TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN49470934.
参考来源
- Sandhu HK, Booth K, Furlan AD, et al. Reducing Opioid Use for Chronic Pain With a Group-Based Intervention: A Randomized Clinical Trial. JAMA. 2023. PMID: 37219554. doi:10.1001/jama.2023.6454
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。